Compare · NVO vs XBIT
NVO vs XBIT
Side-by-side comparison of Novo Nordisk A/S (NVO) and XBiotech Inc. (XBIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and XBIT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2534.8x XBIT ($72.3M).
- Over the past year, NVO is down 45.7% and XBIT is down 18.7% - XBIT leads by 27.0 points.
- NVO has hit the wire 8 times in the past 4 weeks while XBIT has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for XBIT).
- Company
- Novo Nordisk A/S
- XBiotech Inc.
- Price
- $41.01-4.51%
- $2.38+0.42%
- Market cap
- $183.15B
- $72.3M
- 1M return
- -10.44%
- -7.23%
- 1Y return
- -45.66%
- -18.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest XBIT
- SEC Form 10-Q filed by XBiotech Inc.
- Amendment: SEC Form 10-K/A filed by XBiotech Inc.
- SEC Form 10-K filed by XBiotech Inc.
- SEC Form S-8 filed by XBiotech Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.
- XBiotech Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by XBiotech Inc.
- SEC Form 4 filed by Director Rademaker Craig Evan
- SEC Form 4 filed by Director Soffer David Spencer
- SEC Form 4 filed by Director Kuendig Thomas Martin